HCW Biologics (HCWB) shares more than doubled amid heavy trading after the company said Monday that it received US Food and Drug Administration clearance to launch a phase 1 trial to evaluate HCW9302 for treating moderate-to-severe alopecia areata.
Over 313.9 million shares traded intraday versus a daily average of roughly 9.9 million.
GH Research (GHRS) said Monday that a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.
Shares surged 82% as intraday trading volume catapulted to over 8.4 million from a daily average of about 79,000.
Triumph Group (TGI) said Monday that it agreed to be acquired and taken private by the affiliates of Warburg Pincus and Berkshire Partners in a roughly $3 billion all-cash deal.
Shares of the aerospace supplier jumped 34%, with intraday trading volume rising to over 14.4 million compared with a daily average of about 699,000.
Price: 0.66, Change: +0.39, Percent Change: +138.75
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。